Headquartered in West Conshohocken, Pennsylvania, Madrigal Pharmaceuticals operates primarily in the United States, addressing high unmet medical needs in the cardiovascular, metabolic, and liver disease spaces. The company transitioned into a fully integrated commercial organization following the accelerated FDA approval and launch of its flagship product, Rezdiffra, a once-daily, oral, liver-directed thyroid hormone receptor beta (THR-β) agonist. Madrigal's business model is highly specialized, centering almost entirely on the MASH treatment category rather than maintaining a broad, diversified drug portfolio. In addition to its commercialized therapy, the company's pipeline includes early-stage assets such as an oral GLP-1, a DGAT2 inhibitor, and preclinical siRNA programs aimed at developing future combination therapies.
